Brett S Hanscom

7PUBLICATIONS
34CO-AUTHORS
Gene and molecular therapyBehavioural epidemiologyTechnology, crime and surveillanceCancer therapy (excl. chemotherapy and radiation therapy)Epidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 24, 2026
A novel injectable drug-combination nanoparticle containing three antiretrovirals designed for HIV treatment: A first-in-human trial.

|Apr 27, 2026
Prospective HIV RNA Screening With Long-acting Cabotegravir Pre-exposure Prophylaxis in HPTN 083.

|Nov 08, 2025
Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083.

Brett Hanscom, Mark A Marzinke, Xinnong Li

|Jul 01, 2025
Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083.

Todd T Brown, Robert F Arao, Maryam Warsi

|Nov 23, 2024
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083.

Meredith E Clement, Brett Hanscom, Daniel Haines

|Sep 02, 2022
Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial.

Brett S Hanscom, Deborah J Donnell, Thomas R Fleming

Pageof 2

Frequent Collaborators

4 joint publications

Raphael J Landovitz

2 joint publications

Meredith E Clement

2 joint publications

Ryan Kofron

2 joint publications

Deborah J Donnell